Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila

IntroductionIntestinal stem cells (ISCs) possess the ability to self-renew and differentiate, which is essential for maintaining intestinal tissue homeostasis. However, their functionality significantly declines with age, leading to diminished tissue regeneration and an increased risk of age-associa...

Full description

Saved in:
Bibliographic Details
Main Authors: Jinhua Yan, Chenxi Feng, Hanmei Zhang, Ting Luo, Haiyang Chen, Haiou Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1576258/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849710931029786624
author Jinhua Yan
Jinhua Yan
Chenxi Feng
Hanmei Zhang
Ting Luo
Ting Luo
Haiyang Chen
Haiou Chen
author_facet Jinhua Yan
Jinhua Yan
Chenxi Feng
Hanmei Zhang
Ting Luo
Ting Luo
Haiyang Chen
Haiou Chen
author_sort Jinhua Yan
collection DOAJ
description IntroductionIntestinal stem cells (ISCs) possess the ability to self-renew and differentiate, which is essential for maintaining intestinal tissue homeostasis. However, their functionality significantly declines with age, leading to diminished tissue regeneration and an increased risk of age-associated diseases.MethodsThis study investigates the effects of Dapagliflozin (DAPA), a novel insulin sensitizer and SGLT2 inhibitor, on aging ISCs using the Drosophila melanogaster model. Our findings demonstrate that DAPA can inhibit the MAPK signaling pathway, as confirmed by network pharmacology analysis and molecular docking experiments.ResultsDAPA ameliorates ISC aging, improves intestinal function (including enhanced fecal excretion, restored intestinal barrier integrity and acid-base balance), and enhances healthspan. These results highlight the potential of DAPA as an anti-aging therapeutic agent.DiscussionThis study provides new evidence for the application of DAPA as an anti-aging treatment.
format Article
id doaj-art-607e1e04a6104ec9abb88b35dca283db
institution DOAJ
issn 2296-634X
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj-art-607e1e04a6104ec9abb88b35dca283db2025-08-20T03:14:46ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-04-011310.3389/fcell.2025.15762581576258Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in DrosophilaJinhua Yan0Jinhua Yan1Chenxi Feng2Hanmei Zhang3Ting Luo4Ting Luo5Haiyang Chen6Haiou Chen7Center of Gerontology and Geriatrics and Laboratory of Metabolism and Aging Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Medicine, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Medicine, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Medicine, Sichuan University, Chengdu, Sichuan, ChinaCenter of Gerontology and Geriatrics and Laboratory of Metabolism and Aging Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Medicine, Sichuan University, Chengdu, Sichuan, ChinaCenter of Gerontology and Geriatrics and Laboratory of Metabolism and Aging Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaCenter of Gerontology and Geriatrics and Laboratory of Metabolism and Aging Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaIntroductionIntestinal stem cells (ISCs) possess the ability to self-renew and differentiate, which is essential for maintaining intestinal tissue homeostasis. However, their functionality significantly declines with age, leading to diminished tissue regeneration and an increased risk of age-associated diseases.MethodsThis study investigates the effects of Dapagliflozin (DAPA), a novel insulin sensitizer and SGLT2 inhibitor, on aging ISCs using the Drosophila melanogaster model. Our findings demonstrate that DAPA can inhibit the MAPK signaling pathway, as confirmed by network pharmacology analysis and molecular docking experiments.ResultsDAPA ameliorates ISC aging, improves intestinal function (including enhanced fecal excretion, restored intestinal barrier integrity and acid-base balance), and enhances healthspan. These results highlight the potential of DAPA as an anti-aging therapeutic agent.DiscussionThis study provides new evidence for the application of DAPA as an anti-aging treatment.https://www.frontiersin.org/articles/10.3389/fcell.2025.1576258/fulldapagliflozinintestinal stem cellagingMAPK signalingDrosophila
spellingShingle Jinhua Yan
Jinhua Yan
Chenxi Feng
Hanmei Zhang
Ting Luo
Ting Luo
Haiyang Chen
Haiou Chen
Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
Frontiers in Cell and Developmental Biology
dapagliflozin
intestinal stem cell
aging
MAPK signaling
Drosophila
title Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
title_full Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
title_fullStr Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
title_full_unstemmed Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
title_short Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
title_sort dapagliflozin ameliorates intestinal stem cell aging by regulating the mapk signaling pathway in drosophila
topic dapagliflozin
intestinal stem cell
aging
MAPK signaling
Drosophila
url https://www.frontiersin.org/articles/10.3389/fcell.2025.1576258/full
work_keys_str_mv AT jinhuayan dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT jinhuayan dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT chenxifeng dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT hanmeizhang dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT tingluo dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT tingluo dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT haiyangchen dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila
AT haiouchen dapagliflozinamelioratesintestinalstemcellagingbyregulatingthemapksignalingpathwayindrosophila